5 results on '"Cavalcante, Rafael Ciro Marques"'
Search Results
2. Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.
- Author
-
de Souza Araújo, Adriano Antunes, Quintans-Júnior, Lucindo José, Heimfarth, Luana, Schimieguel, Dulce Marta, Corrêa, Cristiane Bani, de Moura, Tatiana Rodrigues, Cavalcante, Rafael Ciro Marques, Grespan, Renata, de Souza Siqueira Quintans, Jullyana, dos Santos, Danillo Menezes, da Silva, Danilo Nobre, de Oliveira, Yrna Lorena Matos, de Franca, Mariana Nobre Farias, da Conceição Silva, Marcílio, de Sá, Darla Lorena Freitas, de Carvalho, Fernanda Oliveira, de Souza, Mércia Feitosa, de Oliveira Góes, Marco Aurélio, Santos, Victor Santana, and Martins-Filho, Paulo Ricardo
- Subjects
COVID-19 pandemic ,SEROPREVALENCE ,SARS-CoV-2 ,COVID-19 ,METROPOLITAN areas ,ANTIBODY titer - Abstract
In this household-based seroepidemiological survey, we analyzed the dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in Sergipe State, Northeast Brazil, the poorest region of the country. A total of 16,547 individuals were tested using a rapid IgM−IgG antibody test and fluorescence immunoassay (FIA). Seroprevalence rates were presented according to age, sex, and geographic region. A comparative analysis was performed between the results obtained in July 2020 (peak of the first wave), August – November 2020 (end of the first wave), and February – March 2021 (beginning of the second wave). Seroprevalence rates in the three phases were estimated at 9.3% (95% CI 8.5–10.1), 12.0% (95% CI 11.2–12.9) and 15.4% (95% CI 14.5–16.4). At the end of the first wave, there was a rise in seroprevalence in the countryside (p < 0.001). At the beginning of the second wave, we found an increase in seroprevalence among women (p < 0.001), adults aged 20 to 59 years (p < 0.001), and the elderly (p < 0.001). In this phase, we found an increase in estimates both in metropolitan areas and in the countryside (p < 0.001). This study showed an increase in SARS-CoV-2 seroprevalence over the first year of the pandemic, with approximately one in six people having anti-SARS-CoV-2 antibodies at the beginning of the second wave of COVID-19. Furthermore, our results suggest a rapid spread of COVID-19 from metropolitan areas to the countryside during the first months of the pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.
- Author
-
de Souza Araújo, Adriano Antunes, Quintans-Júnior, Lucindo José, Heimfarth, Luana, Schimieguel, Dulce Marta, Corrêa, Cristiane Bani, de Moura, Tatiana Rodrigues, Cavalcante, Rafael Ciro Marques, Rodrigues Bomfim, Rangel, Grespan, Renata, Santana Rodrigues, Lorranny, dos Santos, Danillo Menezes, de Sá Resende, Ayane, de Lima Silva, Nathanielly, da Silva Santos, Anna Clara Ramos, Dantas Araújo, Jéssica Maria, de Souza, Mércia Feitosa, de Oliveira Góes, Marco Aurélio, Santana Santos, Victor, and Martins-Filho, Paulo Ricardo
- Abstract
Population-based seroprevalence studies on coronavirus disease 2019 (COVID-19) in low- and middle-income countries are lacking. We investigated the seroprevalence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibodies in Sergipe state, Northeast Brazil, using rapid IgM−IgG antibody test and fluorescence immunoassay. The seroprevalence was 9.3% (95% CI 8.5–10.1), 10.2% (95% CI 9.2–11.3) for women and 7.9% (IC 95% 6.8–9.1) for men (P = 0.004). We found a decline in the prevalence of SARS-CoV-2 antibodies according to age, but the differences were not statistically significant: 0–19 years (9.9%; 95% CI 7.8–12.5), 20–59 years (9.3%; 95% CI 8.4–10.3) and ≥60 years (9.0%; 95% CI 7.5–10.8) (P = 0.517). The metropolitan area had a higher seroprevalence (11.7%, 95% CI 10.3–13.2) than outside municipalities (8.0%, 95% CI 7.2–8.9) (P < 0.001). These findings highlight the importance of serosurveillance to estimate the real impact of the COVID-19 outbreak and thereby provide data to better understand the spread of the virus, as well as providing information to guide stay-at-home measures and other policies. In addition, these results may be useful as basic data to follow the progress of COVID-19 outbreak as social restriction initiatives start to be relaxed in Brazil. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
- Author
-
Nascimento Júnior, José Adão Carvalho, Santos, Anamaria Mendonça, Cavalcante, Rafael Ciro Marques, Quintans-Júnior, Lucindo José, Walker, Cristiani Isabel Banderó, Borges, Lysandro Pinto, Frank, Luiza Abrahão, and Serafini, Mairim Russo
- Subjects
COVID-19 ,SARS-CoV-2 ,MIDDLE East respiratory syndrome ,SARS disease ,COVID-19 vaccines ,GENETIC vectors - Abstract
The last two decades have seen the emergence of several viral outbreaks. Some of them are the severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome 2 (SARS-CoV2) – the cause of the coronavirus disease 2019 (COVID-19). Ever, vaccines for emergency use have been authorized for the control and prevention of COVID-19. Currently, there is an urgent need to develop a vaccine for prophylaxis of COVID-19 and for other future epidemics. This review describes patented vaccines for SARS and MERS-CoV and vaccines developed and approved for emergency use against the new coronavirus (COVID-19). The European Patent Office and the World Intellectual Property Organization were the patent databases used using specific terms. In addition, another search was carried out in the Clinical Trials in search of ongoing clinical studies focused on the COVID-19 vaccine. The patent search showed that most vaccines are based on viral vector platforms, nucleic acids, or protein subunits. The review also includes an overview of completed and ongoing clinical trials for SARS-CoV-2 in several countries. The information provided here lists vaccines for other types of coronavirus that have been used in the development of vaccines for COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Bacillus subtilis Spores as Vaccine Adjuvants: Further Insights into the Mechanisms of Action.
- Author
-
de Souza, Renata Damásio, Batista, Milene Tavares, Luiz, Wilson Barros, Cavalcante, Rafael Ciro Marques, Amorim, Jaime Henrique, Bizerra, Raíza Sales Pereira, Martins, Eduardo Gimenes, and de Souza Ferreira, Luís Carlos
- Subjects
BIOTECHNOLOGY ,BACILLUS subtilis ,BACTERIAL spores ,BACTERIAL vaccines ,DRUG administration ,IMMUNIZATION - Abstract
Bacillus subtilis spores have received growing attention regarding potential biotechnological applications, including the use as probiotics and in vaccine formulations. B. subtilis spores have also been shown to behave as particulate vaccine adjuvants, promoting the increase of antibody responses after co-administration with antigens either admixed or adsorbed on the spore surface. In this study, we further evaluated the immune modulatory properties of B. subtilis spores using a recombinant HIV gag p24 protein as a model antigen. The adjuvant effects of B. subtilis spores were not affected by the genetic background of the mouse lineage and did not induce significant inflammatory or deleterious effects after parenteral administration. Our results demonstrated that co-administration, but not adsorption to the spore surface, enhanced the immunogenicity of that target antigen after subcutaneous administration to BALB/c and C57BL/6 mice. Spores promoted activation of antigen presenting cells as demonstrated by the upregulation of MHC and CD40 molecules and enhanced secretion of pro-inflammatory cytokines by murine dendritic cells. In addition, in vivo studies indicated a direct role of the innate immunity on the immunomodulatory properties of B. subtilis spores, as demonstrated by the lack of adjuvant effects on MyD88 and TLR2 knockout mouse strains. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.